Standard BioTools Inc. Payments for Restructuring
Standard BioTools Inc. (LAB) reported Payments for Restructuring of $8.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-08-05
- Standard BioTools Inc. payments for restructuring for the quarter ending 2026-06-30 was $4.01M.
- Standard BioTools Inc. payments for restructuring for the quarter ending 2026-03-31 was $4.34M.
- Standard BioTools Inc. payments for restructuring for the quarter ending 2025-12-31 was $5.47M, a 403.68% increase year-over-year.
- Standard BioTools Inc. payments for restructuring for the quarter ending 2025-09-30 was $3.83M, a 7.96% increase year-over-year.
- Standard BioTools Inc. payments for restructuring for fiscal 2025 was $13.45M, a 14.50% increase from fiscal 2024.
- Standard BioTools Inc. payments for restructuring for fiscal 2024 was $11.74M, a 14.20% increase from fiscal 2023.
- Standard BioTools Inc. payments for restructuring for fiscal 2023 was $10.28M, a 80.45% increase from fiscal 2022.
- Standard BioTools Inc. payments for restructuring for fiscal 2022 was $5.70M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month | Payments for Restructuring 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $4.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.35M 10-Q · filed 2026-08-05 | $13.82M derived: sum of 3 quarters · filed 2026-08-05 | $17.64M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $4.34M 10-Q · filed 2026-05-06 | $9.81M derived: sum of 2 quarters · filed 2026-05-06 | $13.63M derived: sum of 3 quarters · filed 2026-05-06 | ||
| 2025-12-31 | $5.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $9.29M derived: sum of 2 quarters · filed 2026-03-16 | $13.45M 10-K · filed 2026-03-16 | ||
| 2025-09-30 | $3.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $7.98M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $4.15M 10-Q · filed 2025-08-15 | ||||
| 2024-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $4.63M derived: sum of 2 quarters · filed 2026-03-16 | $9.80M derived: sum of 3 quarters · filed 2026-03-16 | $11.74M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $8.71M derived: sum of 2 quarters · filed 2024-11-06 | $10.66M 10-Q · filed 2024-11-06 | $13.04M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-06-30 | $5.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $7.12M 10-Q · filed 2024-08-06 | $9.49M derived: sum of 3 quarters · filed 2026-03-16 | $11.87M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-03-31 | $1.94M 10-Q · filed 2024-05-09 | $4.32M derived: sum of 2 quarters · filed 2026-03-16 | $6.70M derived: sum of 3 quarters · filed 2026-03-16 | $10.45M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2023-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $4.76M derived: sum of 2 quarters · filed 2026-03-16 | $8.51M derived: sum of 3 quarters · filed 2026-03-16 | $10.28M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $6.13M derived: sum of 2 quarters · filed 2023-11-07 | $7.91M 10-Q · filed 2023-11-07 | $12.38M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.53M 10-Q · filed 2023-08-08 | $10.00M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2023-03-31 | $1.78M 10-Q · filed 2023-05-09 | $6.25M derived: sum of 2 quarters · filed 2025-03-11 | |||
| 2022-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $5.70M 10-K · filed 2025-03-11 | $2.17M 10-K · filed 2023-03-14 | ||
| 2022-09-30 | $1.23M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |